Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FHNW4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,899
Award facts
- Contract value 100% obligated
- $14,898.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $14,898.75 to DMS Pharmaceutical Group Inc. for the supply of Entyvio 300 mg vials, a specialty pharmaceutical product. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order carries a firm fixed-price structure with an ultimate completion date of February 3, 2026, and will be performed at the contractor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for military healthcare operations. The contractor's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHNW4?
SPE2DR26FHNW4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 2, 2026.
How much is contract SPE2DR26FHNW4 worth?
The government has obligated $14,899 on SPE2DR26FHNW4.
Is contract SPE2DR26FHNW4 an order under another contract?
Yes. SPE2DR26FHNW4 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNW4 competed?
The extent of competition for SPE2DR26FHNW4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award